From USD 25.8 billion in 2022 to USD 35.6 billion by 2031, the worldwide asthma market is expected to rise at a CAGR of 4.5%. North America's high frequency and sophisticated healthcare system help it to now control the market.
Millions of people worldwide suffer from asthma, a chronic respiratory illness that keeps driving market expansion. Rising awareness, growing air pollution, and creative therapy development help to expand the industry. For market players, the increasing focus on biologics and tailored medicine offers major chances.
Market Trend: For severe asthma, turn to biologics and targeted treatments.
Particularly for those with severe, uncontrolled asthma, the asthma market is seeing a notable move toward biologics and targeted therapy. Compared to conventional treatments, these cutting-edge medications—including monoclonal antibodies aiming at particular inflammation pathways—offer better efficacy and less side effects. In clinical studies and actual situations, biologics include anti-IgE, anti-IL-5, and anti-IL-4/IL-13 medicines have demonstrated encouraging outcomes. The demand for better management of severe asthma cases that do not react sufficiently to traditional treatments fuels this movement. Research in this field should produce a wider spectrum of targeted treatments as well as maybe more individualized treatment approaches depending on certain patient traits and asthma phenotypes.
Market Driver: Increasing asthma prevalence and related risk factors
One of the main causes of market expansion worldwide is the rising frequency of asthma everywhere. Among the several elements influencing this trend are urbanization, air pollution, changing lifestyles, and genetic susceptibility. The World Health Organisation estimates that over 300 million people worldwide suffer with asthma, and by 2025 the figure is predicted to climb to 400 million. Higher degrees of air pollutants and allergens brought on by industrialization and urban growth have set off asthma symptoms in vulnerable people. Higher reported cases also follow from increased knowledge of asthma and better diagnosis tools. This growing frequency drives demand for both current and new asthma medications since it generates a significant patient pool needing long-term maintenance. Pharmaceutical companies are so heavily funding research and development in order to meet the increasing demand in this industry.
Market Restraint: Patent expirations and growing general competitiveness
The expiring of patents for important asthma drugs and the consequent rise in generic competition provide a major obstacle to the asthma business. Generic copies of long-acting beta-agonists and popular inhaled corticosteroids enter the market as patents for these drugs expire, which lowers market share for branded medications and results in price cuts. This tendency may affect the income sources of big pharmaceutical corporations as well as their capacity for new medication development investment. Although it helps patients in terms of cost, it might stifle field innovation. Companies are reacting by concentrating on creating new combination treatments, investigating alternative delivery systems, and funding biologics with longer patent protection. For established firms in the asthma treatment scene, however, the pressure from generic competition still represents a major obstacle to market development and profitability.
The Drug Class category is dominated by long-term control medications.
Still the pillar of asthma treatment are long-term control drugs, especially inhaled corticosteroids. For those with persistent asthma, these medications significantly lower airway inflammation and stop symptoms, hence improving lung function and quality of life. Their demonstrated effectiveness, recommendations for first-line medication, and the increasing focus on preventative care in asthma control help to explain the predominance of this sector.
Leading the worldwide asthma market is North America.
Driven by high frequency rates, modern healthcare infrastructure, and strong research and development activities, North America rules the worldwide asthma industry. The area gains from more knowledge, early diagnosis, and more healthcare expenditure. Furthermore helping to drive the market are the presence of important players in it and good refund policies. Particularly leading in implementing creative therapies and biologics for severe asthma is the United States, therefore confirming North America's leadership as the biggest regional market for asthma therapy.
The fierce competition among both major pharmaceutical corporations and new players defines the landscape of the asthma market. Important tactics are creating new combination treatments, funding biologics for severe asthma, and broadening product lines by means of mergers and acquisitions. Companies are also emphasizing patient adherence and bettering medicine delivery systems. To provide digital health solutions for asthma control, pharmaceutical businesses and technology companies have become more cooperative on the market. Offering reasonably priced substitutes, generic producers are becoming more popular especially in underdeveloped areas. The competitive scene is overall dynamic, driven by strategic alliances and innovation that shapes the market.
GlaxoSmithKline plc
AstraZeneca plc
Boehringer Ingelheim International GmbH
Novartis AG
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
F. Hoffmann-La Roche Ltd
Sanofi S.A.
Regeneron Pharmaceuticals, Inc.
Genentech, Inc.
1. INTRODUCTION
1.1. Market Definition
1.2. Study Scope
1.3. Currency Conversion
1.4. Study Period (2022- 2031)
1.5. Regional Coverage
2. RESEARCH METHODOLOGY
2.1. Primary Research
2.2. Secondary Research
2.3. Company Share Analysis
2.4. Data Triangulation
3. EXECUTIVE SUMMARY
3.1. Global Asthma Market (2018 – 2022)
3.2. Global Asthma Market (2023 – 2031)
3.2.1. Market Segment By Drug Class (2023 – 2031)
3.2.2. Market Segment By Route of Administration (2023 – 2031)
3.2.3. Market Segment By Distribution Channel (2023 – 2031)
3.2.4. Market Segment By Region (2023 – 2031)
4. MARKET DYNAMICS
4.1. Market Trends
4.1.1. Shift towards biologics and targeted therapies for severe asthma
4.1.2. Increasing focus on digital health solutions for asthma management
4.1.3. Growing emphasis on combination therapies for improved efficacy
4.2. Market Drivers
4.2.1. Rising prevalence of asthma and associated risk factors
4.2.2. Advancements in drug delivery technologies
4.2.3. Increasing healthcare expenditure and awareness in developing countries
4.3. Market Restraints
4.3.1. Patent expirations and increasing generic competition
4.3.2. Stringent regulatory requirements for new drug approvals
4.4. Porter's Five Forces Analysis
4.4.1. Threat of New Entrants
4.4.2. Bargaining Power of Buyers/Consumers
4.4.3. Bargaining Power of Suppliers
4.4.4. Threat of Substitute Products
4.4.5. Intensity of Competitive Rivalry
4.5. Supply Chain Analysis
4.6. Pricing Analysis
4.7. Regulatory Analysis
4.8. Pipeline Analysis
5. BY DRUG CLASS (MARKET VALUE (US$ MILLION) – 2022-2031*)
5.1. Long-term Control Medications
5.2. Quick-relief Medications
5.3. Combination Medications
6. BY ROUTE OF ADMINISTRATION
6.1. Oral
6.2. Inhaled
6.3. Intravenous
7. BY DISTRIBUTION CHANNEL
7.1. Hospital Pharmacies
7.2. Retail Pharmacies
7.3. Online Pharmacies
8. GEOGRAPHY
8.1. North America
8.1.1. United States
8.1.2. Canada
8.1.3. Mexico
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Rest of South America
8.3. Europe
8.3.1. Germany
8.3.2. United Kingdom
8.3.3. France
8.3.4. Italy
8.3.5. Spain
8.3.6. Russia
8.3.7. Rest of Europe
8.4. Asia-Pacific
8.4.1. China
8.4.2. Japan
8.4.3. India
8.4.4. Australia
8.4.5. South Korea
8.4.6. Rest of Asia-Pacific
8.5. Middle-East
8.5.1. UAE
8.5.2. Saudi Arabia
8.5.3. Turkey
8.5.4. Rest of Middle East
8.6. Africa
8.6.1. South Africa
8.6.2. Egypt
8.6.3. Rest of Africa
9. COMPETITVE LANDCAPE
9.1. Key Developments
9.2. Company Market Share Analysis
9.3. Product Benchmarking
10. SWOT ANALYSIS
11. COMPANY PROFILES
11.1. GlaxoSmithKline plc
11.2. AstraZeneca plc
11.3. Boehringer Ingelheim International GmbH
11.4. Novartis AG
11.5. Merck & Co., Inc.
11.6. Teva Pharmaceutical Industries Ltd.
11.7. F. Hoffmann-La Roche Ltd
11.8. Sanofi S.A.
11.9. Regeneron Pharmaceuticals, Inc.
11.10. Genentech, Inc.
11.11. Mylan N.V.
11.12. Lupin Limited (*LIST NOT EXHAUSTIVE)
12. MARKET OPPORTUNITIES
By Drug Class:
Long-term Control Medications
Quick-relief Medications
Combination Medications
By Route of Administration:
Oral
Inhaled
Intravenous
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511
